The Use Of Fibrinogen Concentrates Have Several Advantages Over Other Blood Products
![]() |
| Fibrinogen Concentrates |
Thrombin, factor XIIIa, and plasmin are three enzymes that use it as a
physiological substrate. The traditional sources of fibrinogen, such as fresh
frozen plasma and cryoprecipitate, are now frequently replaced with Fibrinogen Concentrates. A
glycoprotein complex in the blood called fibrinogen (factor I) is involved in
the process of blood clotting. When a tissue or vascular injury occurs, an
enzyme like thrombin converts fibrinogen into fibrin, causing the blood to clot
and stopping the flow of blood. The fibrin seals off the blood vessels to stop
bleeding.
Patients with congenital fibrinogen deficiency, a hereditary condition
where the body's capacity to clot blood is hampered by a lack of fibrinogen
protein, are treated for bleeding using fibrinogen concentrate.
Fibrinogen is a key protein that plays a crucial role in the blood
clotting process. It is a soluble protein that circulates in the blood plasma
and is converted into fibrin by the action of thrombin. Fibrinogen is a large
protein molecule with a molecular weight of approximately 340 kDa. It is
composed of three pairs of polypeptide chains: two identical Aα chains, two
identical Bβ chains, and two identical γ chains. Fibrinogen deficiency can lead
to bleeding disorders, and Fibrinogen
Concentrates are used to treat such conditions.
The use of Fibrinogen
Concentrates has several advantages over other blood products such as fresh
frozen plasma (FFP) or cryoprecipitate. FFP and cryoprecipitate contain
multiple clotting factors, and the use of these products can increase the risk
of transfusion-related complications such as transfusion reactions, infections,
and transfusion-associated circulatory overload. Fibrinogen concentrates, on
the other hand, contain only fibrinogen, reducing the risk of
transfusion-related complications.

Comments
Post a Comment